Overview

A Bioequivalence Study Comparing Amodiaquine Tablet (Pfizer) To Amodiaquine Tablets (Arsuamoon-Guilin China) In Healthy Subjects

Status:
Completed

Trial end date:
2009-07-01

Target enrollment:

Participant gender:

Summary

The study will determine if amodiaquine tablet (Pfizer), an antimalaria agent, is pharmaceutically equivalent to a comparator product (Arsuamoon-Guilin China).

Phase:

Phase 1

Details

Lead Sponsor:

Pfizer

Treatments:

Amodiaquine